Cover Image
市場調查報告書

糖尿病治療藥及藥物輸送手段:下一代型的技術

Next Generation Technologies for Diabetes Therapy and Drug Delivery

出版商 Technical Insights (Frost & Sullivan) 商品編碼 355847
出版日期 內容資訊 英文 95 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
糖尿病治療藥及藥物輸送手段:下一代型的技術 Next Generation Technologies for Diabetes Therapy and Drug Delivery
出版日期: 2016年03月30日 內容資訊: 英文 95 Pages
簡介

糖尿病的患病人數這10年劇增,全球18歲以上的人口約有9%發病。並且預計將成為2030年死因的第7名。第一型糖尿病 (T1DM) 的治療方法,現在最廣泛使用的有頻回胰島素注射療法 (MDI) 。同時,糖尿病治療用的新藥,和新的胰島素輸送投資的開發在全球各國進行。具體來說包含設計奈米醫藥品技術的口服藥和經由肺的給藥法,使用貼片和藥物輸液幫浦的經皮給藥法等,以改善患者的QoL (生活品質) 。製藥企業在醫療設備製造商間構築長期性的聯盟關係,進行糖尿病治療方法的最有效的通知手段的開發。

本報告提供糖尿病的治療藥與其藥物輸送相關最新的技術開發、產品上市的趨勢相關分析,目前技術創新 (革新) 的趨勢,及目前技術水準,各種相關利益者 (利害關係者:製藥企業,生物科技企業,醫療設備企業,相關技術企業) 的產品開發的成果與課題,主要產品比較分析,主要開發中產品、專利的資訊等調查。

第1章 摘要整理

第2章 產業模式與市場趨勢

  • 產業的價值鏈和商務 模式
  • 市場影響要素
  • 市場收益額的成長率:各地區
  • 糖尿病用藥物輸送商務:概要資料

第3章 技術創新的可能性和對臨床現場的適用

  • 糖尿病藥物輸送相關的技術創新的領域
  • 製藥企業、生物科技企業的技術創新
  • 醫療設備企業 (MedTech) 的技術創新
  • 相關技術企業 (SynerTech) 的技術創新
  • 技術創新的模式
  • 開發中的開發中產品

第4章 主要技術創新的概要

  • 製藥、生物科技企業:人體吸入用胰島素粉末
  • 製藥、生物科技企業:TANZEUM
  • 製藥、生物科技企業:XIGDUO XR
  • 製藥、生物科技企業:Xultophy (IDegLira)
  • 製藥、生物科技企業:Smart Insulin
  • 製藥、生物科技企業:膽汁酸微膠囊
  • 醫療設備企業:FreeStyle Libre Flash Glucose Monitoring
  • 醫療設備企業:血糖監測系統用智慧、隱形眼鏡
  • 醫療設備企業:附中空針微針頭、藥丸
  • 醫療設備企業:自我抗體測量用微晶片
  • 醫療設備企業:SmartGuard GlucoSitter
  • 醫療設備企業:iLet Bihormonal Bionic Pancreas
  • 醫療設備企業:ITCA 650
  • 醫療設備企業:G-Pen Mini ™Glucagon Injection
  • 相關技術企業:血糖奈米感測器
  • 相關技術企業:奈米技術的細胞的初始化
  • 相關技術企業:3D Bioplotted Hydrogel Scaffolds
  • 相關技術企業:球狀核酸
  • 相關技術企業:β細胞置換療法的設計
  • 相關技術企業:血糖值反應型的胰島素生成細胞
  • 其他值得注意的創新技術
  • 對電子醫療的糖尿病的適用

第5章 技術比較分析

  • 比較分析用複數標準方法
  • 研究開發 (R&D) 比較分析:架構
  • R&D比較分析:各企業的主要優勢
  • 結論

第6章 知識產權 (IP) 趨勢

第7章 附錄

第8章 關於Frost&Sullivan

目錄
Product Code: D6D9-01-00-00-00

Depicting the Perfect Scenario for Cutting-edge Technology Convergence in Biomedical Sciences

Diabetes has exhibited dramatic increases during the past decade, registering a global prevalence of 9% among adults aged 18 years and older, and is projected to be the 7th-leading cause of death by 2030. The most popular treatment for type 1 diabetes mellitus (T1DM) is multiple daily insulin (MDI) injections. However, researchers globally are working on both the development of novel drugs to fight diabetes, and on the design of novel insulin delivery systems. These delivery systems mostly via use oral and pulmonary routes using nanocarrier-based delivery systems, as well as transdermal delivery to through patches and infusion pumps, which aim to improve the quality of life of diabetic patients.

An important new business model is emerging between large pharmaceutical/biopharmaceutical companies and medical devices firms with the objective of accelerating the delivery of novel therapeutic systems to the industry. Medical device companies and drug manufacturing companies sign long-term partnership agreements to combine their drug delivery devices with the most-active diabetes therapeutics, thereby bringing down the operational costs and saving a significant amount of time during the process.

This research service (RS) examines the current landscape and new trends in diabetes drug delivery, focusing on:

  • Technology trends and capability
  • Stakeholder activities, influence, industry initiatives, and applications targeted
  • Industry initiatives, regulation, and standardization approaches for tackling challenges
  • Technology benchmarking for specific applications

An appendix is included, comprising lists of the major participants in the study and the most notable patents in the field.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Research Scope
  • 2. Research Scope (continued)
  • 3. Research Methodology
  • 4. Key Findings
  • 5. Key Findings (continued)
  • 6. Key Findings (continued)

2. INDUSTRY MODELS AND MARKET TRENDS

  • 1. Industry Value Chain and Business Model
  • 2. Diabetes Drug Delivery Market Impact
  • 3. Diabetes Drug Delivery Market Impact (continued)
  • 4. Diabetes Drug Delivery Regional Revenue Growth
  • 5. Diabetes Drug Delivery Business Facts

3. INNOVATION POTENTIAL AND CLINICAL TRANSLATION

  • 1. Diabetes Drug Delivery Innovation Fields
  • 2. Diabetes Drug Delivery Innovation in Pharma/Biotech
  • 3. Diabetes Drug Delivery Innovation in Medtech
  • 4. Diabetes Drug Delivery Innovation in Synertech
  • 5. Diabetes Drug Delivery Innovation Model
  • 6. Diabetes Drug Delivery Innovation Model (continued)
  • 7. Diabetes Drug Delivery Development Pipeline
  • 8. Diabetes Drug Delivery Development Pipeline(continued)

4. KEY INNOVATIONS PROFILED

  • 1. Pharma/Biotech - Insulin Human Inhalation Powder
  • 2. Pharma/Biotech - TANZEUM (albiglutide)
  • 3. Pharma/Biotech - XIGDUO XR
  • 4. Pharma/Biotech - Xultophy (IDegLira)
  • 5. Pharma/Biotech - Smart Insulin
  • 6. Pharma/Biotech - Bile Acid Microcapsules
  • 7. Medtech - FreeStyle Libre Flash Glucose Monitoring
  • 8. Medtech - Smart Contact Lenses for Glucose Monitoring
  • 9. Medtech - Microneedle Pill with Hollow Needles
  • 10. Medtech - Autoantibody Measuring Microchip
  • 11. Medtech - SmartGuard GlucoSitter
  • 12. Medtech - iLet Bihormonal Bionic Pancreas
  • 13. Medtech - ITCA 650
  • 14. Medtech - G-Pen Mini™ Glucagon Injection
  • 15. Synertech - Glucose Nanosensors
  • 16. Synertech - Cell Reprogramming via Nanotechnology
  • 17. Synertech - 3D Bioplotted Hydrogel Scaffolds
  • 18. Synertech - Spherical Nucleic Acids
  • 19. Synertech - Engineering β-Cell Replacement Therapy
  • 20. Synertech - Glucose-Responsive Insulin-Producing Cells
  • 21. Other Innovative Technologies to Watch
  • 22. Other Innovative Technologies to Watch (continued)
  • 23. Diabetes eHealth Applications to Follow

5. TECHNOLOGY BENCHMARKING

  • 1. Multi-criteria Approach for Benchmarking
  • 2. Multi-criteria Approach for Benchmarking (continued)
  • 3. Multi-criteria Approach for Benchmarking (continued)
  • 4. Multi-criteria Approach for Benchmarking (continued)
  • 5. Multi-criteria Approach for Benchmarking (continued)
  • 6. Multi-criteria Approach for Benchmarking (continued)
  • 7. Multi-criteria Approach for Benchmarking (continued)
  • 8. Multi-criteria Approach for Benchmarking (continued)
  • 9. Multi-criteria Approach for Benchmarking (continued)
  • 10. R&D Benchmarking-Framework
  • 11. R&D Benchmarking-Main Strengths by Company
  • 12. R&D Benchmarking-Main Strengths by Company (continued)
  • 13. R&D Benchmarking-Main Strengths by Company (continued)
  • 14. R&D Benchmarking-Main Strengths by Company (continued)
  • 15. Final Remarks

6. INTELLECTUAL PROPERTY TRENDS

  • 1. Intellectual Property
  • 2. Intellectual Property (continued)
  • 3. Intellectual Property (continued)
  • 4. Intellectual Property (continued)

7. APPENDIX

  • 1. Key Industry Contacts
  • 2. Key Industry Contacts (continued)
  • 3. Key Industry Contacts (continued)
  • 4. Key Academic Contacts
  • 5. Key Academic Contacts (continued)
  • 6. Intellectual Property Sources
  • 7. Key Granted Patents
  • 8. Key Granted Patents (continued)
  • 9. Key Granted Patents (continued)
  • 10. Key Granted Patents (continued)
  • 11. Key Granted Patents (continued)
  • 12. Key Granted Patents (continued)
  • 13. Key Granted Patents (continued)
  • 14. Legal Disclaimer

8. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top